Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin in Juxtafoveal Telangiectasias
NCT00406380Phase 3Withdrawn
- Sponsor
- Asociación para Evitar la Ceguera en México
- Start
- Sep 2006
- Primary completion
- Sep 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bevacizumab in macular telangiectasia (MacTel), sponsored by Asociación para Evitar la Ceguera en México. Primary endpoints: Best Corrected Visual Acuity at 3 months, Fluorescein Angiogram Leakage at 3 months and 1 more. Planned start Sep 2006; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
macular telangiectasia (MacTel)
Beyond the preview
Go deeper on NCT00406380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00406380.